Available online 23 December 2022, 101809
Author links open overlay panelAbstractPsoriatic arthritis (PsA) is a common immune-mediated inflammatory disease (IMID) that can present with a heterogenous clinical phenotype. The advent of advanced therapies has substantially improved patient outcomes, but many patients still have suboptimal or unsustained response, resulting in morbidity, structural damage and functional impairment. There remains a need for better therapeutic options and precision medicine approaches to improve outcomes for patients with PsA. This review synthesises recently approved the state-of-the-art therapeutics for PsA, including inhibitors of IL-23, Janus kinase (JAK), tyrosine kinase 2 (TYK2) and dual-target IL-17A/F. The evidence base for emerging therapeutics, including MK-2 inhibitors, nano-IL-17 inhibitors, nanobodies and other dual-target therapies for PsA is also reviewed. Potential future therapeutic strategies and unmet research needs are discussed.
KeywordsPsoriatic arthritis (PsA)
Spondylarthritis
Therapeutics
IL17
IL12/23
Janus kinases
Tyrosine kinase 2
Mitogen activated protein kinase 2
Nano-IL-17 inhibitors
Nanobodies
© 2022 The Author(s). Published by Elsevier Ltd.
留言 (0)